Boston Scientific

Boston Scientific is a global medical technology company headquartered in Marlborough, United States, renowned for its comprehensive portfolio of medical solutions designed to improve patient health. While the company does not operate a traditional corporate venture capital fund with a publicly defined investment thesis and check size ranges, it is highly active in strategic corporate development. This involves both significant mergers and acquisitions (M&A) and strategic equity investments in emerging medical technology companies. These investments are primarily driven by a desire to access innovative technologies and solutions that align with Boston Scientific's core therapeutic areas, including cardiology, urology, gastroenterology, and neuromodulation.

A cornerstone of Boston Scientific's growth strategy is its robust M&A activity, through which it acquires companies developing promising and complementary technologies. For example, the company entered into an agreement in 2024 to acquire Axonics, Inc. for approximately $3.7 billion, significantly expanding its urology portfolio. Similarly, in 2022, Boston Scientific acquired Apollo Endosurgery for $615 million, enhancing its endoscopy offerings. These large-scale acquisitions demonstrate the company's commitment to integrating advanced medical innovations directly into its business.

Beyond outright acquisitions, Boston Scientific also engages in strategic minority equity investments in venture funding rounds. These investments typically target later-stage startups (Series B, C, and D) that have demonstrated clinical potential or market traction, rather than early-stage seed or Series A companies. The purpose of these strategic stakes is to foster collaborative development, gain early access to groundbreaking technologies, and potentially pave the way for future commercial partnerships or full acquisitions. While specific "first cheque" sizes for these strategic equity investments are not publicly disclosed, based on their participation in substantial funding rounds for growth-stage companies, it is reasonable to estimate that Boston Scientific's typical initial strategic equity investments range from approximately $5 million for early-growth stage companies to $50 million for more mature private companies. This reflects their focus on substantial, strategically aligned opportunities rather than small, speculative venture bets.